MPN | Tumor

CURE’s myeloproliferative neoplasms (MPN) page is an extensive resource of cancer information featuring the latest MPN news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on myeloproliferative neoplasms.

MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

January 12th 2023

Before closing out their program on myeloproliferative neoplasms, Rami Komrokji, MD, and Ruben Mesa, MD, discuss the potential for progression of MF to acute myeloid leukemia and highlight key treatment strategies.

Myelofibrosis: Novel Treatment Strategies and Combination Therapies

January 5th 2023

Comprehensive discussion on the management of myelofibrosis, covering both monotherapy and combination therapy strategies.

Novel Treatment Strategies in Essential Thrombocythemia and Polycythemia Vera

January 5th 2023

Focusing on clinical trials and novel therapies, Rami Komrokji, MD, and Ruben Mesa, MD, share their hope for the future management of essential thrombocythemia and polycythemia vera.

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

December 29th 2022

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Healthcare Team Members Involved in Treating Myeloproliferative Neoplasms

December 29th 2022

Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.

Overview of Treatment Options for Myelofibrosis

December 22nd 2022

Switching their focus to myelofibrosis, Rami Komrokji, MD, and Ruben Mesa, MD, consider mainstay treatment options in this setting.

Overview on the Management of Essential Thrombocythemia and Polycythemia Vera

December 22nd 2022

Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera.

Educated Patient® MPN Summit Myelofibrosis Panel: November 19, 2022

December 18th 2022

Watch Dr. Aaron Gerds and Dr. Andrew Kuykendall answer questions about myelofibrosis during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Myelofibrosis Second-Line Treatment and Beyond Presentation: November 19, 2022

December 17th 2022

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit First-line Treatment in Myelofibrosis Presentation: November 19, 2022

December 16th 2022

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

How Are Myeloproliferative Neoplasms Diagnosed?

December 15th 2022

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms.

A Background on Myeloproliferative Neoplasms

December 15th 2022

Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Educated Patient® MPN Summit Polycythemia Vera Panel: November 19, 2022

December 15th 2022

Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.

Ongoing Research May Lead to ‘Exciting’ Advancements for Myelofibrosis Years Down the Line

December 14th 2022

Research efforts will improve the lives of patients with myelofibrosis, though those advancements may take years to come, an expert said.

Educated Patient® MPN Summit Future Treatment of Polycythemia Vera Presentation: November 19, 2022

December 14th 2022

Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Current Treatment Options in Polycythemia Vera Presentation: November 19, 2022

December 13th 2022

Watch Dr. Jamile M. Shammo, from Northwestern University Feinberg School of Medicine, discuss current treatment options in polycythemia vera during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Essential Thrombocythemia Panel: November 19, 2022

December 12th 2022

Watch Dr. Aaron Gerds and Dr. Douglas Tremblay answer questions about essential thrombocythemia during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Current and Future Treatments of Essential Thrombocythemia Presentation: November 19, 2022

December 11th 2022

Watch Dr. Douglas A. Tremblay, from Mount Sinai, discuss treatment for essential thrombocythemia during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Defining Essential Thrombocythemia Risk Presentation: November 19, 2022

December 10th 2022

Watch Dr. Aaron T. Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss essential thrombocythemia risk during the CURE Educated Patient MPN Summit.

CURE® Salutes 8 Individuals’ Efforts During 10th Annual MPN Heroes® Program

December 10th 2022

CURE® celebrated the work of eight individuals who go above and beyond to better the lives of people living with myeloproliferative neoplasms, a group of blood cancers.

With Transplant the Only Cure for Myelofibrosis, Clinical Trials, Patient-Provider Communication Is Key

November 14th 2022

Patients with myelofibrosis should be open about their treatment goals with their providers, and potentially consider getting a second opinion or participating in a clinical trial, one expert says.

Novel Drug Decreases Fibrosis in Myelofibrosis, A Type of Blood Cancer

September 30th 2022

Treatment with the novel drug GB2064 was associated with decreased fibrosis in patients with myelofibrosis, a type of blood cancer, according to findings from an ongoing phase 2 trial.

How the Name Change to Myeloproliferative Neoplasms Affected People With the Disease

September 23rd 2022

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest.

Study Will Analyze Imetelstat-Jakafi Combination for Myelofibrosis

August 30th 2022

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

FDA Approves Pemazyre for Myeloid or Lymphoid Neoplasms With FGFR1-Rearrangements

August 26th 2022

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement.

Ayvakit Improves Disease Burden, Quality of Life in Mastocytosis

August 23rd 2022

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial.

FDA OKs New Drug Application for Momelotinib to Treat Myelofibrosis

August 18th 2022

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

‘Listen to Your Patient,’ Says Cancer Caregiver

July 22nd 2022

A cancer caregiver recommends that other caregivers become well-versed in their loved one’s disease.

Cancer Caregiver Realizes the Impact of His Advocacy Work

July 18th 2022

When Jeff Bushnell was contacted by a patient with an MPN who lived in the Philippines, he realized how his advocacy work was impacting patients around the globe.

Oncologist Who Specializes in Treating Rare Blood Cancers ‘Learns from Patients Every Day’

July 15th 2022

An expert from the Tisch Cancer Institute discusses how he learns from patients and their caregivers, and how their insight has helped lead advancements in the treatment of myeloproliferative neoplasms, a group of rare blood cancers.

NEXT PAGE
PREVIOUS PAGE